WuXi AppTec Co., Ltd. (WUXAY)
| Market Cap | 39.32B |
| Revenue (ttm) | 5.79B |
| Net Income (ttm) | 1.92B |
| Shares Out | n/a |
| EPS (ttm) | 0.56 |
| PE Ratio | 20.45 |
| Forward PE | 22.00 |
| Dividend | 0.14 (1.12%) |
| Ex-Dividend Date | May 19, 2025 |
| Volume | 100 |
| Average Volume | 4,972 |
| Open | 13.81 |
| Previous Close | 12.63 |
| Day's Range | 13.81 - 14.95 |
| 52-Week Range | 3.56 - 14.95 |
| Beta | 0.76 |
| RSI | 86.87 |
| Earnings Date | Jul 27, 2025 |
About WuXi AppTec
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula... [Read more]
Financial Performance
In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.
Financial numbers in CNY Financial StatementsNews
WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript
WuXi AppTec Co., Ltd. (OTCPK:WUXIF) Q2 2025 Earnings Conference Call July 28, 2025 9:00 PM ET Company Participants Ming Shi - Senior VP & CFO Minzhang Chen - Co-CEO & Executive Director Qing Yang - Co...
WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY
Total Revenue Reached RMB11.14 Billion in the Second Quarter, Up 20.4% Year-over-Year; among which Revenue from Continuing Operations Reached RMB11.05 Billion, Up 24.9% Year-over-Year Total Revenue Re...
WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
SHANGHAI , July 10, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-t...
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
SHANGHAI , July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies i...
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
SHANGHAI , June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI , June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
Focus: China pharma projects disrupted by Sino-US tensions
Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of th...
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI , June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript
WuXi AppTec Co.
WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY
Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Continuing Operations Reached RMB9.39 Billion, Up 23.1% Year-over-Year Net Profit Attributable to the Owners of...
WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections
SHANGHAI , March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences in...
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year 2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023) Full-Year Net Pr...
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI , Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ind...
WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year
SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating
COUVET, Switzerland , Nov. 14, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life s...
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
SHANGHAI , Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-...
WuXi AppTec to raise $500 mln in convertible bond sale as US restrictions loom
China's WuXi AppTec , will raise $500 million in a convertible bond sale, according to a regulatory filing on Tuesday, a month after the U.S. passed rules to restrict business with the firm on nationa...
US bill to restrict business with China's WuXi AppTec, BGI passes House
The U.S. House of Representatives on Monday passed a bill that aims to restrict business with China's WuXi AppTec , BGI and several other biotech companies on national security grounds.
US House committee to vote on bill to restrict BGI, WuXi AppTec
U.S. legislation that would restrict business with China's BGI, WuXi AppTec and certain other biotech companies on national security grounds will be voted on by a committee in the House of Representat...
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties
A new version of a bill that would restrict U.S. business with China's WuXi AppTec, BGI and other biotechnology companies of concern would allow companies until 2032 to end work with the Chinese firms...
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reac...
Exclusive: China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators
U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without...
China's WuXi AppTec In Crosshairs of US Draft Biosecurity Bill
A draft US law is casting a cloud over some Chinese pharma firms, as it aims to block certain foreign biotech companies from accessing US federal contracts on national security grounds. Bloomberg's Mi...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributable to the Owners of the Company [1] Increased 9.0% to RMB9,607 Million; Dilut...